Treatment with etamsylate reduces haemolactia in lactating dairy cows

This Research Communication describes the efficacy of etamsylate to reduce haemolactia in dairy cows. A dairy cow with haemolactia produces milk that is reddish or pinkish due to the presence of blood. Haemolactia causes economic loss because bloody milk is rejected by the industry and the consumers. A total of 58 dairy cows with haemolactia were included in the study and randomly divided into treated (n = 31) and control (n = 27) groups. Treatment consisted of three consecutive daily doses of etamsylate at 15 mg/kg, delivered intramuscularly. Milk production was recorded daily for 7 d, whether or not blood was detected in milk. The mean number of days with the presence of blood in milk in the treatment group was significantly lower (3·4 d) than in the control group (4·9 d). Treatment with etamsylate did not significantly affect milk yield. In conclusion, treatment with etamsylate reduces the number of days blood is observed in milk and it does not have any negative effect on milk production

ALL-268 genetic classification of B-Cell precursor adult acute lymphoblastic leukemia patients enrolled in LAL19 trial from the pethema group: response to treatment and survival

Context: B-cell precursor acute lymphoblastic leukemia (BCP ALL) is a genetically heterogeneous neoplasm with >20 biologic subtypes. Each subtype shows specific genetic traits that determine relapse risk and patients' survival. Objectives: To establish the genetic subtype (primary alteration) of adult BCP ALL patients enrolled in the PETHEMA LAL19 trial (NCT 04179929) and to correlate them with measurable residual disease (MRD) level and survival. Patients and Methods: In the LAL19 trial (NCT04179929), Ph-negative patients (18–65 y) with MRD≥0.01% at day+35 or high-risk genetics receive alloHSCT and MRD<0.01% patients with standard-risk genetics receive maintenance chemotherapy. The genetic analyses are centralized: FISH and NGS DNA panel (Hospital de Salamanca), RNAseq panel (Hospital 12 de Octubre), FISH panel (Hospital La Fe), and SNP array (Josep Carreras Institute/ICO-Hospital Germans Trias i Pujol). MRD determinations are centrally done by next-generation flow cytometry in the Cytometry Service, NUCLEUS, University of Salamanca. Results: The genetic subtype was identified in 54% (82/152) of patients. The most recurrent subtypes were KMT2Ar (11%), Ph-like (mostly CRLF2::IGH, 11%), low-hypodiploid (7%), PAX5 P80R (7%), high-hyperdiploid (6%), and t(1;19)/TCF3::PBX1 (6%). In addition, t(12;21)/ETV6::RUNX1, ZNF384r, and iAMP21 subtypes (1.5% each) and MEF2Dr, MYCr, IDH1 R132 subtypes (<1% each) were found. Regarding secondary alterations, NRAS (15%), TP53 (13%), PAX5 (13%), and KRAS (10%) mutations were the most frequently observed. Twelve patients were refractory (mainly low-hypodiploid, Ph-like, MYCr, and B-other/unclassified patients). Statistically significant differences were observed for day+35 MRD levels between genetic subtypes. Ph-like, low-hypodiploid, and KMT2Ar showed lower frequencies of MRD<0.01% (17%, 33%, and 57%, respectively) than patients with PAX5P80R (100%), t(1;19)/TCF3::PBX1 (83%), and high-hyperdiploid (75%) (P=0.006). Despite the short median follow-up (11 months), differences in response to treatment were reflected in patients' survival. Significant differences in survival were observed between poor-response subtypes (Ph-like, KMT2Ar, and low-hypodiploid) and good-response subtypes (PAX5 P80R, t(1;19)/TCF3::PBX1, and high-hyperdiploid). Conclusions: Knowing the genetic subtype of each ALL is crucial to better predict relapse risk and offer the best (personalized) treatment for each patient

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features

Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in >90% of cases. Patients with low risk cytogenetic features account for 80% of CMML cases and often fall into the low risk categories of CMML prognostic scoring systems, but the outcome differs considerably among them. We performed targeted deep sequencing of 83 myeloid-related genes in 56 CMML patients with low risk cytogenetic features or uninformative conventional cytogenetics (CC) at diagnosis, with the aim to identify the genetic characteristics of patients with a more aggressive disease. Targeted sequencing was also performed in a subset of these patients at time of acute myeloid leukemia (AML) transformation. Overall, 98% of patients harbored at least one mutation. Mutations in cell signaling genes were acquired at time of AML progression. Mutations in ASXL1, EZH2 and NRAS correlated with higher risk features and shorter overall survival (OS) and progression free survival (PFS). Patients with SRSF2 mutations associated with poorer OS, while absence of TET2 mutations (TET2wt) was predictive of shorter PFS. A decrease in OS and PFS was observed as the number of adverse risk gene mutations (ASXL1, EZH2, NRAS and SRSF2) increased. On multivariate analyses, CMML-specific scoring system (CPSS) and presence of adverse risk gene mutations remained significant for OS, while CPSS and TET2wt were predictive of PFS. These results confirm that mutation analysis can add prognostic value to patients with CMML and low risk cytogenetic features or uninformative CC

Mitjans de comunicació: I. La ràdio. II. La televisió

Materiales que constituyen un crédito común del área de lengua del ciclo 12-16 indicado para alumnos de tercer y cuarto curso de Educación Secundaria Obligatoria. Se ha demostrado que es un estímulo para el proceso de aprendizaje del alumno. Trata los siguientes aspectos: reconocimiento del proceso de comunicación, de los mensajes orales, de la comunicación oral formal y espontánea y el uso de la lengua en Radio y Televisión. Incluye todo el diseño del crédito y el material didáctico para el profesor y para el alumno relacionado con las actividades base del crédito: la realización de un programa de televisión y otro de radio.Generalitat de Catalunya. Servei d'Ordenació CurricularCataluñaES

Effects of butyrate feed supplementation on gilthead sea bream (Sparus aurata) growth performance and intestinal health: A transcriptomic approach

Poster presentado en la Aquaculture conference "To the next 40 years of sustainable global aquaculture" celebrada en Gran Canaria del 3 al 7 de noviembre de 2013The aim of the present study was to evaluate the effects of a short fatty acid, the commercial butyrate product (BP-70, ®Norel), on gilthead sea bream performance and intestinal health. Juvenile fish of 25 g initial body weight were distributed in 90-L triplicate tanks/group (15 fish/tank). Fish were fed plant protein-based diets with 20% fish meal and 35% plant oil at the expense of fish oil, and with increasing levels of BP-70 (0%, 0.2%, 0.4%, 0.8%) for 9 weeks. No significant effects of butyrate supplementation were found on growth rates, feed conversion ratio, or retention of N and lipids. No effects were found on hepatosomatic index or viscerosomatic index, but the gut index (fish weight/intestine length) was progressively and significantly increased with butyrate supplementation. Butyrate also increased plasma glucose levels and liver glycogen depots, which highly supports a sparing effect of butyrate on the utilization of glucose as a metabolic fuel. A PCR-array of 90 genes was used to characterize the intestinal gene expression pattern of the two extreme groups (0%, 0.8% diets). Genes were selected as markers of intestine cell proliferation and differentiation, intestinal architecture and permeability, enterocyte mass and epithelia damage, intestinal immune-surveillance and mitochondria activity. The differentially expressed genes of all these categories showed that butyrate supplementation clearly induced a healthy intestine condition. In particular, components of the Hedgehog, bone morphogenic protein and Notch signalling pathways were up-regulated in butyrate treated fish, which would orchestrate a complex regulatory network promoting intestine cell differentiation rather than stem cell proliferation. This agrees with the lowered expression of the proliferating cell nuclear antigen (PCNA), as evidenced by RT-PCR and immunocytochemistry. Butyrate also improved the intestine barrier function, up-regulating the expression of several components of tight junctions (occludin, claudin 12, claudin 15, tight junction protein ZO-1, and coxsackievirus and adenovirus receptor homolog), and altered the expression of nuclear-encoded mitochondrial genes, up regulating the expression of master transcription factors, mitochondrial protein translocases and oxidative enzymes of the tricarboxylic acid cycle, and down-regulated the expression of mitochondrial molecular chaperones of the Hsp 10 family. This expression pattern is indicative of a mitochondrial phenotype with a ¿high power¿ activity and a low risk of oxidative stress. In addition, butyrate supplementation altered the expression of interleukin 7, nucleotide-binding protein oligomerization domain-containing protein 1, vimentin, macrophage mannose receptor 1 and C-C motif chemokine 20, leading to an anti-inflammatory gene expression pattern. Therefore, butyrate supplementation as a whole is a very promising approach to improve the health condition of gilthead sea bream intestine.Peer Reviewe